Duration: 2:09

4 views

0

This vid helps get started w/ GSK trelegy ellipta.

i. Trelegy Ellipta is a prescription medication developed by GlaxoSmithKline (GSK) for the treatment of respiratory conditions. It's the first once-daily single inhaler triple therapy approved for the maintenance treatment of both asthma and chronic obstructive pulmonary disease (COPD) in adults. Here are some key details:

**Composition:**
- Trelegy Ellipta combines three active ingredients: fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta2-adrenergic agonist).

**Indications:**
- For COPD, it's indicated for patients who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations, and who require additional treatment of airflow obstruction or are already receiving umeclidinium.
- For asthma, it's indicated for patients aged 18 years and older who are not adequately controlled on a long-acting beta agonist (LABA) combined with an inhaled corticosteroid (ICS).

**Dosage:**
- The FDA-approved strength for both COPD and asthma is fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 mcg. There is an additional strength for asthma alone, which is 200/62.5/25 mcg.

**Usage:**
- It's administered once daily using the Ellipta dry powder inhaler.

**Not for Acute Symptoms:**
- Trelegy Ellipta is not indicated for relief of acute bronchospasm.

It's important for patients to use Trelegy Ellipta as prescribed by their healthcare provider and to discuss any concerns or side effects they may experience.